Core Viewpoint - Kahn Swick & Foti, LLC is investigating iRhythm Technologies, Inc. following a Warning Letter from the FDA regarding non-conformities in medical device regulations and subsequent legal actions against the company and its executives [1][2][3]. Group 1: FDA Warning and Compliance Issues - On May 30, 2023, iRhythm Technologies received a Warning Letter from the FDA concerning non-conformities related to the Zio AT System, specifically addressing deficiencies in medical device reporting and quality system requirements [2]. - The FDA's concerns included undisclosed risks to patients, such as limitations in the transmission of arrhythmia or heart irregularity events [2]. Group 2: Legal Actions and Investigations - Following the FDA's Warning Letter, iRhythm and certain executives were sued in a securities class action lawsuit for failing to disclose material information, violating federal securities laws [3]. - The court has denied the company's motion to dismiss the case, allowing the lawsuit to proceed, while KSF's investigation focuses on potential breaches of fiduciary duties by iRhythm's officers and directors [3].

NEW YORK, July 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Petco Health and Wellness Company, Inc. (NASDAQ: WOOF).Shareholders who purchased shares of WOOF during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/petco-loss-submission-form/?id=155419&from=4CLASS PERIOD: January ...

SAN FRANCISCO, June 26, 2025 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises UnitedHealth Group investors that the firm is investigating potential legal claims following revelations that the company is under criminal investigation for fraud and allegedly made false statements to investors. Current shareholders are encouraged to contact the firm.On May 13, 2025, UnitedHealth suspended its 2025 fiscal guidance and announced that its CEO Andrew Witty had resigned for "personal reasons." Two days later, ...

SAN FRANCISCO, June 25, 2025 /PRNewswire/ -- Abacus Global Management, Inc. (NASDAQ: ABL) is under mounting pressure as its stock continues to slide, driven by a series of damning reports from Morpheus Research—a newly formed investigative group led by analysts who previously worked at the renowned Hindenburg Research. Despite Abacus's public denials and the announcement of a $20 million share repurchase program, investor confidence remains shaken, with shares now down more than 36% over the past month.Prom ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to allegations of misleading statements and concealment of material facts related to the company's capital allocation and dividend strategy [1][2]. Allegations - The complaint alleges that Organon's management provided overly positive statements while concealing the prioritization of debt reduction following the acquisition of Dermavant, which led to a significant reduction in the quarterly dividend by 70% [1]. - Following the announcement of the dividend cut, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [1]. Class Action Details - Shareholders who purchased shares during the class period from October 31, 2024, to April 30, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for July 22, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case, with no cost or obligation to participate [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices, aiming to ensure companies adhere to responsible business practices [3].

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of UnitedHealth Group Incorporated (NYSE: UNH). Shareholders who purchased shares of UNH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/unitedhealth-group-incorporated-loss-submission-form/?id=150518&from=3  ...

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Strategy Incorporated (NASDAQ: MSTR). Shareholders who purchased shares of MSTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/strategy-incorporated-loss-submission-form/?id=150526&from=3 CLASS PERIOD: Ap ...

NEW YORK, May 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of UnitedHealth Group Incorporated (NYSE: UNH).Shareholders who purchased shares of UNH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/unitedhealth-group-incorporated-loss-submission-form/?id=150502&from=4CLASS PE ...

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for failing to disclose material information, leading to significant financial losses for investors during the specified Class Period [3][4]. Group 1: Lawsuit Details - Investors who purchased Organon securities between October 31, 2024, and April 30, 2025, have until July 22, 2025, to file lead plaintiff applications [1][2]. - The lawsuit alleges that Organon and certain executives violated federal securities laws by not disclosing critical information during the Class Period [3]. Group 2: Financial Impact - On March 10, 2025, Organon announced a drastic reduction in its dividend payout from $0.28 to $0.02, which contradicted previous assurances to investors regarding the importance of maintaining the dividend [4]. - Following the announcement, Organon's share price plummeted over 27%, dropping from $12.93 on April 30, 2025, to $9.45 on May 1, 2025 [4]. Group 3: Legal Representation - Kahn Swick & Foti, LLC, a prominent securities litigation law firm, is representing the investors in this case [5]. - The firm has a strong track record, being ranked among the top 10 firms nationally based on total settlement value [5].

Group 1 - The Justice Department is not planning to prosecute Boeing regarding the crashes of the 737 Max, allowing the company to avoid a guilty plea [1] - Boeing had previously agreed to plead guilty in a deal with the Justice Department after being found in violation of a 2021 agreement related to the crashes, but a judge rejected this plea deal due to concerns about diversity, equity, and inclusion [2] - The fraud charge against Boeing is linked to the development of the 737 Max, with accusations of misleading regulators about a flight-control system involved in the crashes [3]